Free Trial

Rentokil Initial (OTCMKTS:RTOKY) Stock Passes Above Two Hundred Day Moving Average - Here's Why

Rentokil Initial logo with Business Services background

Rentokil Initial plc (OTCMKTS:RTOKY - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $23.81 and traded as high as $24.30. Rentokil Initial shares last traded at $24.28, with a volume of 890,958 shares trading hands.

Rentokil Initial Trading Up 0.5%

The stock's 50 day moving average price is $23.61 and its 200 day moving average price is $23.77.

Rentokil Initial Company Profile

(Get Free Report)

Rentokil Initial plc, together with its subsidiaries, provides route-based services in North America, the United Kingdom, rest of Europe, Asia, the Pacific, and internationally. It offers a range of pest control services for rodents, and flying and crawling insects, as well as other forms of wildlife management for commercial and residential customers.

Featured Stories

Should You Invest $1,000 in Rentokil Initial Right Now?

Before you consider Rentokil Initial, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rentokil Initial wasn't on the list.

While Rentokil Initial currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines